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REVIEw
therapeutic Advances in the Management of
Huntington’s disease
Ganiy Opeyemi Abdulrahman, Jr.
Cardiff University School of Medicine, Cardiff, United Kingdom
Trinucleotide repeat disorders are a set of genetic disorders characterized by the expansion
of certain genes of a segment of DNA that contains a repeat of three nucleotides, thus ex-
ceeding the normal stable threshold. These repeats in the DNA cause repeats of a specific
amino acid in the protein sequence, and it is the repeated amino acid that results in a de-
fective protein. Huntington’s disease is a well-known genetic disorder associated with trin-
ucleotide repeat expansions. Patients first present clinically in midlife and manifest a typical
phenotype of sporadic, rapid, and involuntary control of limb movement; stiffness of limbs;
impaired cognition; severe psychiatric disturbances; and ultimately, death. There have been
a number of therapeutic advances in the treatment of Huntington’s disease, such as foetal
neural transplantation, RNA interference, and transglutaminase inhibitor. Although there is
intensive research into Huntington’s disease and recent findings seem promising, effective
therapeutic strategies may not be developed until the next few decades.
introduction
Trinucleotide repeat disorders are a set
of genetic disorders characterized by the ex-
pansion of certain genes of a segment of
DNA that contains a repeat of three nu-
cleotides, thus exceeding the normal stable
threshold [1]. There is usually an increase in
the number of triplet repeats as the gene is
passed from generation to generation, result-
ing in abnormalities in gene expression and
function.  Examples  of  diseases  that  are
caused by triplet repeat expansion are Frag-
ile  X  syndrome,  Myotonic  dystrophy,
Friedreich ataxia, and Huntington’s disease.
It is important to understand the mechanism
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cleotideof trinucleotide repeat disorders because many
of the recent successes in their therapies have
been  based  on  the  understanding  of  their
pathophysiology. This paper is aimed at ex-
plaining the genetic basis of trinucleotide re-
peat  disorders  and  will  also  discuss  the
cellular/molecular mechanism that underlie
recent advances in the therapy of a named
triplet repeat expansion disorder: Hunting-
ton’s disease. While there is active ongoing re-
search into several potential therapies, this
paper would highlight five specific therapies
from various experiments.
trinucleotide (“triplet”) 
repeAt disorders
Triplet expansion is caused by slip-
page during DNA replication [2]. As a re-
sult  of  the  repetitive  nature  of  DNA
sequence in these regions, there may be
formation of “loop out” structures during
DNA replication while maintaining com-
plementary base pairing between the par-
ent  strand  and  daughter  strand  being
synthesized. There is an increase in the
number of repeats if the loop out structure
is formed from the sequence on the daugh-
ter strand, while there is a decrease if the
loop out structure is formed from the par-
ent strand. There appears to be a clear bias
toward continued expansion of the size of
the repeat unit array, and it is the repeated
amino acids that result in defective pro-
teins.
Although approximately 30 disorders
have now been identified as being caused by
trinucleotide repeats, this unusual type of
mutation was first discovered in humans in
the medical condition known as Fragile X
syndrome in 1991 [3]. Many of these disor-
ders are rare, but mostly affect the central
nervous system. While they are all caused
by the dynamic mutations of triplet repeats,
there are significant differences among these
disorders. Among the differences are the
base sequence of the repeat; the location of
the repeat within genes; the pathogenesis of
the disease; the size of the repeat in unaf-
fected and affected individuals; and parent-
of-origin effects on repeat expansion [4].
Despite several researches, according to
Turnpenny and Ellard, the precise mecha-
nisms by which disease is caused by triplet
repeat expansions are still unknown [5]. Dy-
namic trinucleotide repeats may be within
coding  or  non-coding  regions  of  genes,
which may be a contributory factor to the
variation in their pathogenic mechanisms. 
Research  has  shown  that  there  is  a
strong correlation between the number of re-
peats and the severity of the disease. For ex-
ample, in the case of myotonic dystrophy
(DM†), normal individuals usually have five
to 37 copies of CTG repeats, while those
with 50 to 80 copies could be mildly af-
fected or have no symptoms at all; however,
those with more than 80 copies to several
thousand copies of the repeat sequence usu-
ally present with full-blown myotonic dys-
trophy [6]. The CTG repeats in myotonic
dystrophy occur in the 3’ untranslated region
of a DM candidate gene [7]. 
Triplet repeat expansions usually occur
over a number of generations within a fam-
ily, and the number of repeats often increases
with  succeeding  generations.  Therefore,
symptoms of the disease usually manifest at
an earlier age in the offspring than in the par-
ents, and the severity of the disease increases
in subsequent generations [8]. This phenom-
enon is known as anticipation. Although this
phenomenon was controversial among sci-
entists for several years, recent discovery in
molecular genetics has shown that anticipa-
tion does have a biological basis.
polyglutAMine (polyQ) diseAses
In many of the trinucleotide repeat dis-
orders, the repeated codon is CAG, which
codes for glutamine in a coding region, re-
sulting in a polyglutamine tract. These dis-
orders  are  commonly  referred  to  as
polyglutamine (PolyQ) diseases. The abnor-
mal  protein  conformation  resulting  from
PolyQ  expansion  seems  to  be  central  to
pathogenesis [9]. It has been suggested that
triplet expansion increases the probability
that PolyQ will adopt a novel abnormal con-
formation [10]. Studies have been conducted
to support the concept of altered conforma-
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antibodies  preferentially  bind  expanded
PolyQ, while in some other studies in dis-
ease  tissue,  transfected  cells  and  animal
models have revealed that expanded PolyQ
proteins form insoluble intracellular inclu-
sions [10]. However, it is still unclear how
the altered conformation leads to neurode-
generation.
In the remaining disorders, the repeated
codons do not code for glutamine and are re-
ferred  to  as  non-polyglutamine  diseases.
Huntington’s disease belongs to the subset of
polyglutamine diseases. Other diseases in
this  group  include  dentatorubropalli-
doluysian atrophy, spinobulbar muscle atro-
phy or Kennedy disease, and Spinocerebellar
ataxia Types 1, 2, 3, 6, 7, and 17.
Huntington’s diseAse
Huntington’s  disease  (HD)  is  a  well-
known genetic disorder associated with trinu-
cleotide  repeat  expansions.  It  was  first
described by an American physician, George
Huntington, in 1872 after he studied several
affected individuals and also noted observa-
tions made by his father and grandfather who
were also physicians [11]. Its mode of inheri-
tance is autosomal dominant, and its preva-
lence is about 5 in 100,000 worldwide [12].
Penetrance is almost 100 percent as individu-
als with the dominant allele eventually de-
velop the disease. The average age of onset is
38 years, though the timing ranges from 25 to
70 years. However, recent studies claim that
approximately 5 percent of HD cases have
presented before 20 years of age [5]. Patients
first present clinically in midlife and manifest
a typical phenotype of sporadic, rapid, and in-
voluntary control of limb movement; stiffness
of limbs; impaired cognition; severe psychi-
atric disturbances; and ultimately, death. 
MoleculAr biology of 
Huntington’s diseAse
HD is a single gene disease with auto-
somal  dominant  inheritance  pattern.  Al-
though the disease locus of HD was mapped
to chromosome 4p16 by the G8 marker in
the early 1980s, the HD gene was not cloned
until 1993 [13]. It has been suggested that
HD is caused by the mutation of the gene
IT15, which contains 67 exons and encodes
a  3144-amino-acid  protein  called  “hunt-
ingtin” [6]. The function of huntingtin is un-
clear. Nasir and colleagues suggest that it is
essential for development and that absence
of huntingtin is lethal in mice [14]. They
concluded in their study that the HD gene is
essential for postimplantation development
and that it may play a significant role in the
normal functioning of the basal ganglia. It
has also been claimed that wild-type hunt-
ingtin up-regulates the expression of Brain
Derived Neurotrophic Factor (BDNF) at the
transcription level; however, the mechanism
by which huntingtin regulates gene expres-
sion has not been determined [15].
The normal repeat number of CAG is
10-26. CAG encodes the amino acid gluta-
mine within the huntingtin gene on chromo-
some 4, and it is not toxic in itself as it is
present in all humans. However, it has been
suggested that expansion of polyglutamine
tract results in aggregate formation that may
become toxic and could be one of the factors
responsible for HD as aggregates are never
observed in the brains of unaffected individ-
uals [16,17]. It has been suggested that indi-
viduals with more than 39 will almost always
show manifestations of HD [18], with the
largest expansion observed being 121 trinu-
cleotides [19]. Conscientious studies of peo-
ple with HD have shown that the cause may
be heterogeneous. According to Lutz, stud-
ies among HD patients have revealed that ap-
proximately 70 percent of the variation in the
age of onset of the disease is linked to the
size of the CAG repeats, while 13 percent of
variation in the onset has been attributed to
polymorphism in the GRIK2 gene, whose
product forms part of the subunit of the ex-
citatory glutamate receptor [20]. Therefore,
there are other factors that can affect the
onset, severity, and outcome of HD.
current MAnAgeMent
At this time, there is no cure for HD.
The aim of current treatment strategies is to
313 Abdulrahman: Therapeutic advances in the management of HDmanage  the  symptoms  and  improve  the
quality of life of the patients. It is important
to determine whether patients require treat-
ment when they present. In the early stages,
the chorea may not be interfering with their
lifestyle and so may not require treatment.
However, if the symptoms begin to affect
their lifestyle such as in walking, writing,
and eating, then intervention becomes a ne-
cessity. Management of HD patients should
be  multidisciplinary.  Hence,  if  they  are
falling at home, for example, as a result of
their progressive symptoms, it may be im-
portant to involve the occupational thera-
pists who would assess the facilities in the
patient’s home and then suggest modifica-
tions that would suit the patient’s needs. The
physiotherapists can also help optimize mo-
bility  and  maintain  independence.  If  the
non-drug management strategies fail, then
drugs such as tetrabenazine could be tried.
Tetrabenazine is efficient in the management
of HD and has been shown to reduce chorea.
This is, in fact, the only drug approved by
the  U.S.  Food  and  Drug  Administration
(FDA) for HD [21]. Tetrabenazine is a drug
used for the symptomatic treatment of hy-
perkinetic  movement  disorder.  Tetra-
benazine  works  mainly  as  a  vesicular
monoamine transporter (VMAT) inhibitor,
therefore  promoting  the  early  metabolic
degradation of monoamines, especially the
neurotransmitter dopamine. In the central
nervous system, VMAT 2 is the only trans-
porter that transports cytoplasmic dopamine
into synaptic vesicles for storage and subse-
quent exocytotic release [22].
It is also important to assess patients for
depression and suicidal thoughts so as to
prescribe antidepressants if necessary.
tHerApeutic AdvAnces
Several studies have been carried out to
demonstrate the abnormalities in the brain
of individuals with HD, in anticipation that
this could possibly help in its treatment. Ac-
cording to Agamanolis, for example, the
brain of individuals with HD shows atrophy
of the caudate nucleus and putamen and di-
latation of the anterior horns of the lateral
ventricles on gross examination [23]. Sim-
mons and colleagues also state that radio-
logical investigations of four patients with
HD reveal that the caudate nucleus and cor-
pus striatum were atrophic [24].
Biochemical study of neurotransmitter
changes in the brain in HD has shown that
there is a significant reduction in the en-
zymes producing gamma-aminobutyric acid
and acetylcholine in the striatum, indicating
the  extensive  loss  of  GABA-ergic  and
cholinergic striatal neurones [25]. Although
most therapeutic advances in publication
have only been tested on animal models,
they offer insight into possible treatment of
HD in the near future.
foetAl neurAl trAnsplAntAtion
As the striatum commonly degenerates
in HD, resulting in loss of motor and cogni-
tive functions, efforts have been made to re-
store these functions by transplanting foetal
striatal neuroblasts into the striata of HD pa-
tients. However, this therapy has not been
very successful in the long term. In a study
by Bachoud-L￩vi and colleagues in which
five patients were grafted with human foetal
neuroblasts, there was an increase in meta-
bolic activity in various subnuclei of the
striatum in three of the five patients, al-
though there was a progressive deterioration
in the two other patients 2 years after sur-
gery [26]. There was also an improvement
in motor and cognitive functions in the same
three patients [26]. However, 4 to 6 years
after surgery, clinical improvement initially
observed in the three patients began to de-
cline and dystonia deteriorated consistently,
while the two patients who did not benefit
from the transplantation continued to dete-
riorate in a comparable way to non-grafted
HD patients [27]. Therefore, although neu-
ronal transplantation may provide improve-
ment  and  stability  initially,  it  is  not  a
permanent cure for HD.
rnA interference
RNA  interference  is  a  biological
process currently being studied as a poten-
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interference (RNAi) is a natural, selective
method of turning off genes, which can be
induced by the production of small interfer-
ing  RNAs  (siRNAs)  formed  by  a  guide
strand and a passenger strand. The discov-
ery  of  RNA  interference  emerged  from
work on the genetic modification of plants
in the late 1980s. In an attempt to deepen
the violet hue of petunias by expressing
higher levels of an enzyme involved in the
synthesis of the pigment, many white flow-
ers appeared following the introduction of
extra copies of the gene. For unknown rea-
sons at the time, the introduction of addi-
tional copies of the gene had resulted in the
suppression of gene expression rather than
the expected increase in expression [28,29].
The phenomenon was later observed in the
filamentous fungus Neurospora crassa and
the nematode worm Caenorhabditis ele-
gans. Initial attempts to induce RNA inter-
ference in human cells were unsuccessful as
the introduction of double-stranded RNA
into mammalian cells resulted in the inhibi-
tion of all gene expression and rapid cell
death.  However,  the  breakthrough  came
when short, double-stranded RNA mole-
cules were shown not to induce the inter-
feron  response,  which  usually  cause  the
inhibition of all gene expression [30]. RNA
interference is now frequently used in bio-
logical and biomedical research to study the
effect of blocking the expression of a par-
ticular  gene.  Proteins  such  as  Drosha,
DGCR8, and argonaute (Ago) participate in
RNA processing. Drosha and DGCR8 form
a complex that initiates the maturation of
micro-RNA by precise cleavage of the stem
loops that are embedded in primary tran-
scripts  (pri-miRNAs)  [31].  Furthermore,
Drosha facilitates the overall production
rate of miRNA by generating the 3’ pro-
truding ends, which are recognized by Exp5
and Dicer [32,33,34]. Neither DGCR8 nor
Drosha alone are active in pri-miRNA pro-
cessing, but combining the two proteins re-
stores  this  activity,  suggesting  that  both
proteins play crucial roles in pri-miRNA
processing [35,36]. The processing of pri-
mRNA is a critical step in miRNA biogen-
esis  because  it  defines  the  miRNA  se-
quences embedded in long pri-miRNAs by
generating one end of the molecule [31].
The resulting pre-miRNAs, following the
initial processing, are exported by the nu-
clear factor, Exp5 [34,37,38]. Dicer, a cyto-
plasmic RNase III type protein, then dices
the  transported  pre-miRNAs  to  generate
miRNA duplexes [39,40,41]. Ago 2 is an es-
sential component of RNA-induced silenc-
ing complex (RISC) that cleaves siRNA and
mRNA target when they are bound together
by complementary base pairing. The miR-
NAs then bind to their target mRNAs to in-
duce translational repression and inhibition
of protein synthesis. It has been demon-
strated that a sole injection of cholesterol-
conjugated small interfering RNA duplexes
(cc-siRNA) targeting huntingtin (Htt) gene
into the adult striatum of a viral transgenic
mouse model of HD silences mutant Htt, at-
tenuates neuronal pathology, and delays the
unusual behavioral phenotype observed in
the mouse. In a study by DiFiglia and col-
leagues, for example, an adeno-associated
virus containing either wild-type (18 CAG)
or expanded (100 CAG) Htt cDNA encod-
ing Htt 1-400 and siRNA were injected into
a mouse striata [42]. It was observed that
treatment of the mice that had the mutant
Htt with cc-siRNA-Htt prolonged survival
of striatal neurones, lowered neuropil ag-
gregates,  and  diminished  inclusion  size.
siRNA reduces the production of mutant Htt
protein and silences its expression via RNA
interference.
trAnsglutAMinAse inHibitor
Transglutaminases are a family of en-
zymes that catalyze the formation of a co-
valent bond between a free amino group and
the gamma-carboxamid group of protein- or
peptide-bound glutamine. They form exten-
sively cross-linked, generally insoluble pro-
tein polymers and have been implicated in a
number of medical conditions such as celiac
disease [43], Parkinson’s [44], and Hunting-
ton’s disease [45]. Recent research suggests
that people suffering from Parkinson’s and
Huntington’s diseases may have an unusu-
315 Abdulrahman: Therapeutic advances in the management of HDally high level of a type of transglutaminase
― tissue transglutaminase.
Karpuj  and  colleagues  demonstrated
that inhibition of transglutaminase (TGase)
could provide a new treatment approach to
HD [46]. It has been suggested that TGase
could be significant to the pathogenesis of
HD,  via  cross-linking  huntingtin.  Cross-
linking is the formation of bonds to link one
polymer chain to another. It is thought that
this promotes the formation of the protein
aggregates that cause HD. When the com-
petitive inhibitor of TGase, cystamine, is ad-
ministered to transgenic mice expressing
exon-1  of  huntingtin  containing  an  ex-
panded repeat of polyglutamine, it is ob-
served  that  the  course  of  their  HD-like
disease is distorted. It is known that cysta-
mine inactivates TGase via a disulfide-ex-
change reaction ― a process of activation or
inactivation of proteins by the folding and
unfolding of the amino acids that produce
the proteins [47]. Furthermore, it is a pri-
mary amine, thus it is a good substrate for
TGase and serves as a TGase competitor by
obstructing access to the enzyme’s active
site for the glutamine residues in proteins
like huntingtin, therefore limiting TGase ac-
tivity. When cystamine is administered in-
traperitoneally, it enters the brain, where it
inhibits TGase activity. Karpuj and associ-
ates state that when treatment started fol-
lowing  the  manifestation  of  abnormal
movements, cystamine prolonged survival,
lowered  associated  tremor  and  irregular
movements, and improved weight loss [46].
Therefore, inhibition of TGase could be use-
ful in the treatment of HD in humans, al-
though  with  experiments  still  in  animal
models, trials in humans would not be ex-
pected in the next few years. Furthermore,
the fact that it appears promising in animal
models does not necessarily imply that it
would be successful in humans.
HuMAn single-cHAin fv 
Antibodies 
A single-chain Fv antibody is a fusion
protein of the variable regions of the heavy
and light chains of immunoglobulins which
is connected with a shorter linker peptide of
about 10 to 25 amino acids. It involves the
removal of the constant regions and the in-
troduction of a linker, although the protein
retains the specificity of the original im-
munoglobulins. Although recent works on
neurodegenerative diseases have shown in
vitro that  precise  engineered  antibody
species, peptides, or other general agents
could restrain the formation of protein ag-
gregates, Wolfgang and colleagues claim
that when using a Drosophila model of HD,
they succeeded in the intrabody-mediated in
vivo suppression of the neuropathology and
also prolonged life expectancy [48]. Intra-
cellularly expressed single-chain Fv (sFv)
binds with a distinctive HD protein, and it
has been demonstrated that anti-N-terminal
huntingtin intrabodies (C4 sFv) decrease ag-
gregation and cellular toxicity in cells and
tissue culture models of HD. Lecerf and col-
leagues claim that anti-huntingtin sFv fused
with a nuclear localisation signal retargeted
huntingtin analogues to cell nuclei, which
provides further evidence of the anti-hunt-
ingtin  sFv  specificity  [49].  It  has  been
shown that when genes for sFVs are intro-
duced into cells and expressed intracellu-
larly,  the  intrabodies  produced  can  bind
stoichiometrically with the target protein
and specifically block the lethal effects of
pathogenic agents [50]. Therefore, the use
of intrabodies could be a therapeutic ap-
proach to treating HD in humans in a distant
future.
ubiQuilin
As  expanded  polyglutamine  (PolyQ)
tracts have been implicated in protein ag-
gregation and cytotoxicity in HD, ubiquilin
has been discovered to reduce protein ag-
gregation and toxicity induced by PolyQ in
cells and animal models of HD. Ubiquilin is
a ubiquitin-like (UBL) protein and has an N-
terminal  UBL  domain  and  a  C-terminal
ubiquitin-associated (UBA) domain. Ubiq-
uitin is a highly conserved 76 amino acid
protein [51], and ubiquilin-1 is one of the
four members of the ubiquilin protein fam-
ily. Wang and associates state that overex-
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tion and toxicity of green fluorescent protein
(GFP)–huntingtin fusion protein containing
74 polyQ repeats, while a decrease in the
level of ubiquilin resulted in increased ag-
gregation  and  cytotoxicity  [52].  When
ubiquilin-1 is overexpressed in cells and in a
Caenorhabditis elegans animal model of
HD, the co-expression of ubiquilin reduces
the formation of aggregates and can both
prevent  and  salvage  the  motility  defect
caused by GFP–Htt(Q55). Ubiqulin proteins
belong to the family of UBL-UBA proteins,
which regulate the ubiquinated-dependent
proteasomal degradation of cellular proteins
[53]. The UBA domain, which is a tight
ubiquitin binder, mediates ubiquilin’s inter-
action  with  polyubiquitins.  It  has  been
demonstrated in several researches that both
in vitro and in vivo, ubiquilin proteins bind
to and co-localize with polyQ aggregates
[54], thus blocking the toxic effect of pro-
tein aggregates. Ubiquilin suppresses cell
death induced by PolyQ in HeLa cells and
primary cortical neurons. Ubiquilin could be
particularly beneficial as it has the ability to
differentially distinguish between toxic and
non-toxic polyglutamine proteins, thus the
inherited mutant copy of CAG allele in HD
can be selectively eliminated without de-
stroying the proteins encoded by non-ex-
panded CAG allele. 
conclusion
The genetics and some therapeutic ad-
vances in the management of HD have been
discussed. Most of these therapies focus on
the development of neuroprotective strate-
gies, with the aim of delaying the onset and
slow the progression of HD. As the onset of
neurodegenerative processes begin long be-
fore the clinical manifestations of HD, it is
also important to develop laboratory meth-
ods of monitoring disease progression be-
fore the onset of clinical symptoms. Most of
the advances discussed are still ongoing;
therefore, it is hoped that the final outcome
would become more apparent in the very
near future. Although there is intensive re-
search into Huntington’s disease and recent
findings seem promising, effective thera-
peutic strategies may not be developed until
the next few decades. This is because many
of the laboratory breakthroughs prove to be
unsuccessful in humans for a variety of un-
known reasons. It is difficult, at this stage,
to suggest that one potential treatment is bet-
ter than the other as most of them have not
been tried in humans so as to evaluate their
effect, hence the reason why all therapeutic
options should be explored by researchers.
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